Overview

Tokai Pharmaceuticals is a biopharmaceutical company previously focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The ARMOR2 and ARMOR3-SV clinical trials of Tokai’s drug candidate, galeterone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been closed, with only patients in ARMOR2 long-term extension continuing treatment at this time. Plans remain in effect to present data from the ARMOR3-SV trial in a scientific forum once fully available and analyzed. Assessment of plans for galeterone, the ARDA platform and Tokai’s AR-V7 assay work are underway at this time.
Stock Performance TKAI (Common Stock) $0.82 Stock is Down 0.01 (2.38%)03/30/1712:07 p.m. ET
Stock chart for: TKAI.O.  Currently trading at $0.82 with a 52 week high of $8.80 and a 52 week low of $0.73.
Data provided by Nasdaq. Minimum 15 minutes delayed.See more
Recent NewsMore >>
  
12/22/16Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement
Transaction to create NASDAQ-listed pharmaceutical company focused on the development and commercialization of ear, nose, and throat (ENT) products Gregory J. Flesher to be Named President and Chief Executive Officer of the Combined Company BOSTON, Mass., IRVINE, Calif., & REHOVOT, Israel--(BUSINESS WIRE)--Dec. 22, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) and Otic Pharma Ltd., a privately-held, clinical-stage pharmaceutical comp... 
Download PDFPrinter Friendly Version
09/08/16Tokai Pharmaceuticals Announces Review of Strategic Alternatives
BOSTON--(BUSINESS WIRE)--Sep. 8, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that its Board of Directors has initiated a review of strategic alternatives for the company focused on maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated a... 
Download PDFPrinter Friendly Version
07/29/16Tokai Pharmaceuticals Announces Reduction in Force
BOSTON--(BUSINESS WIRE)--Jul. 29, 2016-- Tokai Pharmaceuticals Inc. (NASDAQ: TKAI), a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it is reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees, under a plan expected to be largely completed by the end of the third quarter of 2016. This ... 
Download PDFPrinter Friendly Version
EventsMore >>
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Tokai Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 
Investor Contact
Argot Partners
E-mail: tokai@argotpartners.com

Media Contact
Ten Bridge Communications
E-mail: dan@tenbridgecommunications.com

Data provided by Nasdaq. Minimum 15 minutes delayed.
Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet